Thus, the early emergence of RAS-MAPK signaling reactivation through acquired resistance mutations and upstream reactivation of GFR underscores the strong need for RAS signaling in KRASG12C-mutant cancers as well as the major role of tumor heterogeneity in resistance to OFF-state KRASG12C inhibitors. The gene discussed is RAPGEF5; the disease is cancer.